New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug - solution for injection - 25µg/0.5ml - active: salmonella typhi vi polysaccharide 25ug excipient: dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate dihydrate phenol sodium chloride sodium hydroxide water for injection - typhim vi™ is indicated for active immunisation against typhoid fever caused by salmonella typhi in individuals 2 years of age and over.

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - vi polysaccharide, of salmonella, typhi - solution for injection - vi polysaccharide of salmonella typhi 1 µg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - salmonella typhi vi polysaccharide, quantity: 0.025 mg - injection, solution - excipient ingredients: monobasic sodium phosphate; phenol; water for injections; sodium chloride; dibasic sodium phosphate dihydrate - for the active immunisation against typhoid fever, in subjects over 5 years of age. indications as at 9 october 2000: typhim vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)); hepatitis a virus formaldehyde inactivated, gbm strain 160 u - solution for injection - active: salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection active: hepatitis a virus formaldehyde inactivated, gbm strain 160 u excipient: aluminium hydroxide as aluminium formaldehyde medium 199 phenoxyethanol as 2-phenoxyethanol solution 2.5µl - vivaxim® is indicated for simultaneous active immunisation against typhoid fever and hepatitis a virus infections in subjects aged 16 and older.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmonella typhi, vi antigen - solution for injection in pre-filled syringe - 50.0 microgram/ml - typhoid vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - salmonella typhi vi capsular polysaccharide - solution for injection - 50microgram/1ml

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - vi polysaccharide, of salmonella, typhi - solution for injection - vi polysaccharide of salmonella typhi 25 µg - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - hepatit a virus antigen, vi polysaccharide of salmonella typhi - suspension for injection - %v/v - bacterial and viral vaccines, combined

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - salmonella typhi vi capsular polysaccharide - solution for injection - 50microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus (hm175 strain) inactivated; salmonella typhi (ty2 strain) vi capsular polysaccharide - suspension for injection